Heron Therapeutics Submits ZYNRELEF® Supplement to FDA
Company Announcements

Heron Therapeutics Submits ZYNRELEF® Supplement to FDA

An announcement from Heron Therapeutics (HRTX) is now available.

Heron Therapeutics, Inc. has announced the submission of a Prior Approval Supplement for its ZYNRELEF® extended-release solution to the FDA. This development could be significant for investors tracking the company’s progress in enhancing its pain management portfolio. The press release detailing this submission is expected to provide more insights but is not considered a formal regulatory filing.

For an in-depth examination of HRTX stock, go to TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskHeron Therapeutics Strengthens Leadership with New Board Appointment
TheFlyHeron Therapeutics reaffirms availability of Cinvant, Sustol and Aponvie
TheFlyHeron Therapeutics: FDA approves prior supplement application for ZYNRELEF
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App